First Bio-Similar Drug Passed FDA's Stringent Evaluation Procedure

March 7, 2015 7:53 AM

15 0

First Bio-Similar Drug Passed FDA's Stringent Evaluation Procedure

The Food and Drug Administration has sanction the first supposed biosimilar drug for utilization in the United States, preparing for less lavish choices to a whole class of complex and expensive medications.

The medication, called Zarxio, delivered by Sandoz, is utilized to help avert infections in cancer patients undergoing chemotherapy. It is a close duplicate of a current medication called Neupogen, made by Amgen. It was approved in Europe in 2009 as Zarzio yet has not been utilized in the United Sta...

Also read: Mike Pence: Trump's Taiwan Call Was Just 'Courtesy'

Read more

To category page

Loading...